HAWK Biosystems
Derio
About HAWK Biosystems
HAWK Biosystems is to be the platform in cancer diagnostics, bringing precision to cancer patient treatment. This will enable solution of the current problems, which lie in precisely targeting therapies to disease drivers. Fastbase provides a fast and efficient platform technology to measure drug target function. The benefits of precision medicine that can be provided by Fastbase would be to deliver treatment to patients selected to respond to therapy, stop the treatment of patients who will not respond, improve patient outcomes and quality of life and also reduce drug costs. Fastbase will be a major player for collaborative opportunities with European Health system.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Total funding: $1.1M
- Last round: Grant (Feb 2024)
- Website: hawkbiosystems.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/hawk-biosystems-116663 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.